FASENRA, also known by its generic name benralizumab, is a monoclonal antibody medication designed for the treatment of severe eosinophilic asthma in patients aged 12 years and older. It works by targeting and reducing the levels of eosinophils, a type of white blood cell that plays a key role in the inflammation and airway constriction associated with severe asthma. Administered through subcutaneous injection, FASENRA helps in decreasing the frequency of asthma exacerbations, improving breathing, and may reduce the need for oral corticosteroids. It is typically prescribed for individuals whose asthma is not well controlled with their current asthma medicines. As a targeted therapy, FASENRA is an example of precision medicine, offering a tailored approach to asthma management for patients with eosinophilic phenotype asthma.